BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 26, 2026
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Biopharmaceutical collaborations: November 2019

Dec. 27, 2019
Biopharma licensings, joint ventures and collaborations in November 2019.
Read More

Money raised by biopharma: 2019 vs. 2018

Dec. 27, 2019
Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.
Read More

Biopharma money raised: Jan. 1-Dec. 20, 2019

Dec. 27, 2019
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Speech bubbles
Best of 'Word on the Street' part 1

Perspectives on the year: The industry has its say on the markets, M&A and gene therapy

Dec. 24, 2019
By Peter Winter
Throughout the year we have published the views of company executives, government regulators, industry analysts and scientists on a variety of topics and, in our popular annual feature, we include a selection of these that paints a picture of the significant events that shaped 2019. The major talking point was on the capital markets front where investors turned their backs on the biopharmaceutical sector for most of the year returned big time in the final quarter.
Read More

Biggest gainers and losers for the week of Dec. 16-20, 2019

Dec. 20, 2019
The top 10 biopharma stock gainers and losers for the week.
Read More
FDA Approved stamp with blister pack

Dec. 13-19, 2019 week in review: FDA in approval mode

Dec. 20, 2019
A quick look back at top stories.
Read More

Biopharma money raised: Jan. 1-Dec. 19, 2019

Dec. 20, 2019
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2019 vs. 2018

Dec. 20, 2019
Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.
Read More
Blocks spelling out 2019, 2020, trends

Med tech exits year with top performance, tax repeal; enters 2020 facing China tariffs, Medicare for All, increasing FDA control

Dec. 20, 2019
By Karen Carey
Wells Fargo Securities LLC recently published The MedTech Manual – 2020 Outlook, in which it says the medical device sector “will continue to be a port in the storm because the political focus will remain on drug pricing and increasing access to [health care].” Overall, the industry has performed quite well in comparison with other health care sectors during 2019. The financial firm’s senior analyst Larry Biegelsen and colleagues wrote that they expect the medical device sector to continue moving in a positive direction despite Medicare for All (MFA) rhetoric and an upcoming presidential election.
Read More

American Society of Hematology (Orlando, Fla.)

Dec. 20, 2019
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology in Orlando, Fla.
Read More
Previous 1 2 … 296 297 298 299 300 301 302 303 304 … 314 315 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 22, 2026.
  • Brain and DNA

    Sangamo presents primate data for prion suppressor ST-506

    BioWorld Science
    Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
  • TREM2 agonists detailed in Pfizer patent

    BioWorld Science
    Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
  • Selection Therapeutics identifies new Kv1.3 blockers

    BioWorld Science
    Selection Therapeutics GmbH has discovered new potassium voltage-gated channel subfamily A member 3 (KCNA3; Kv1.3) blockers potentially useful for the treatment...
  • Ignis Therapeutics synthesizes new muscarinic M4 receptor PAMs

    BioWorld Science
    Ignis Therapeutics (Suzhou) Co. Ltd. has patented new muscarinic M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing